BioCentury | Dec 31, 2020
Regulation

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

...the NRDL with greater than RMB1 billion in annual sales, including stroke therapies butylphthalide from CSPC Pharmaceutical Group Ltd....
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

...as well as existing investors BioTrack Capital, Yingke PE, Atlas Venture and entities associated with CSPC Pharmaceutical Group Ltd....
BioCentury | May 1, 2020
Regulation

China's proposed annual NRDL revisions could increase pricing pressure

...pricing pressure particularly to long-covered drugs with limited competition such as stroke therapy butylphthalide from CSPC Pharmaceutical Group Ltd....
BioCentury | Mar 26, 2020
Regulation

China’s NMPA suspends Abraxane imports after U.S. inspection

...remediation efforts. Morgan Stanley’s Yolandu Hu said that Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) and CSPC Pharmaceutical Group Ltd....
BioCentury | Dec 31, 2019
Company News

Dec. 31 Company Quick Takes: A first for BeiGene; plus MorphoSys, Junshi-CSPC, Acceleron-Fulcrum and Solasia-EditForce

...lymphoma. The anti-CD19 antibody has breakthrough therapy designation. Junshi, CSPC end deal for PD-1 blocker CSPC Pharmaceutical Group Ltd....
...specific terms were not disclosed. BioCentury Staff Tuoyi, toripalimab (JS001) tislelizumab (BGB-A317) Solasia Pharma K.K. BeiGene Ltd. Shanghai Junshi Biosciences Co. Ltd. CSPC Pharmaceutical Group Ltd. Programmed...
BioCentury | Mar 15, 2019
Finance

HaiHe's listing recipe

...companies. HaiHe narrowed its focus to oncology in February when it formed a JV with CSPC Pharmaceutical Group Ltd....
BioCentury | Mar 13, 2019
Politics & Policy

China releases timeline, priority diseases for revised reimbursement list

...drugs could benefit from the revision, with possible inclusion of drugs from 3SBio Inc. (HKSE:1530), CSPC Pharmaceutical Group Ltd....
...HK$14.60 and Hengrui gained RMB0.07 to RMB69.88. CSPC fell HK$0.32 to HK$13.32. Hongjiang Li, Staff Writer 3SBio Inc. CSPC Pharmaceutical Group Ltd. Innovent...
BioCentury | Feb 21, 2019
Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

...Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop...
...receptor Shanghai HaiHe Biopharma Co. Ltd., Shanghai, China CSPC Pharmaceutical Group Ltd. (HKSE:1093), Hong Kong, China Business: Other Hongjiang Li CSPC Pharmaceutical Group Ltd. Haihe...
BioCentury | Feb 19, 2019
Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

...Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop...
...kinase; COX-2 - Cyclooxygenase-2; FGFR - Fibroblast growth factor receptor; PTGER4 - Prostanoid EP4 receptor Hongjiang Li CSPC Pharmaceutical Group Ltd. Haihe...
BioCentury | Feb 13, 2019
Financial News

HaiHe raises $147M in series B to advance cancer candidates

...pipeline in a series B round led by Huagai Capital. Also participating were Yingke PE, CSPC Pharmaceutical Group Ltd....
Items per page:
1 - 10 of 26
BioCentury | Dec 31, 2020
Regulation

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

...the NRDL with greater than RMB1 billion in annual sales, including stroke therapies butylphthalide from CSPC Pharmaceutical Group Ltd....
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

...as well as existing investors BioTrack Capital, Yingke PE, Atlas Venture and entities associated with CSPC Pharmaceutical Group Ltd....
BioCentury | May 1, 2020
Regulation

China's proposed annual NRDL revisions could increase pricing pressure

...pricing pressure particularly to long-covered drugs with limited competition such as stroke therapy butylphthalide from CSPC Pharmaceutical Group Ltd....
BioCentury | Mar 26, 2020
Regulation

China’s NMPA suspends Abraxane imports after U.S. inspection

...remediation efforts. Morgan Stanley’s Yolandu Hu said that Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) and CSPC Pharmaceutical Group Ltd....
BioCentury | Dec 31, 2019
Company News

Dec. 31 Company Quick Takes: A first for BeiGene; plus MorphoSys, Junshi-CSPC, Acceleron-Fulcrum and Solasia-EditForce

...lymphoma. The anti-CD19 antibody has breakthrough therapy designation. Junshi, CSPC end deal for PD-1 blocker CSPC Pharmaceutical Group Ltd....
...specific terms were not disclosed. BioCentury Staff Tuoyi, toripalimab (JS001) tislelizumab (BGB-A317) Solasia Pharma K.K. BeiGene Ltd. Shanghai Junshi Biosciences Co. Ltd. CSPC Pharmaceutical Group Ltd. Programmed...
BioCentury | Mar 15, 2019
Finance

HaiHe's listing recipe

...companies. HaiHe narrowed its focus to oncology in February when it formed a JV with CSPC Pharmaceutical Group Ltd....
BioCentury | Mar 13, 2019
Politics & Policy

China releases timeline, priority diseases for revised reimbursement list

...drugs could benefit from the revision, with possible inclusion of drugs from 3SBio Inc. (HKSE:1530), CSPC Pharmaceutical Group Ltd....
...HK$14.60 and Hengrui gained RMB0.07 to RMB69.88. CSPC fell HK$0.32 to HK$13.32. Hongjiang Li, Staff Writer 3SBio Inc. CSPC Pharmaceutical Group Ltd. Innovent...
BioCentury | Feb 21, 2019
Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

...Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop...
...receptor Shanghai HaiHe Biopharma Co. Ltd., Shanghai, China CSPC Pharmaceutical Group Ltd. (HKSE:1093), Hong Kong, China Business: Other Hongjiang Li CSPC Pharmaceutical Group Ltd. Haihe...
BioCentury | Feb 19, 2019
Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

...Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop...
...kinase; COX-2 - Cyclooxygenase-2; FGFR - Fibroblast growth factor receptor; PTGER4 - Prostanoid EP4 receptor Hongjiang Li CSPC Pharmaceutical Group Ltd. Haihe...
BioCentury | Feb 13, 2019
Financial News

HaiHe raises $147M in series B to advance cancer candidates

...pipeline in a series B round led by Huagai Capital. Also participating were Yingke PE, CSPC Pharmaceutical Group Ltd....
Items per page:
1 - 10 of 26